

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 4 | 13 | — | — | 17 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 3 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
| Drug common name | Tesaglitazar |
| INN | tesaglitazar |
| Description | Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes.
|
| Classification | Small molecule |
| Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (not thiazolidene derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O |
| PDB | — |
| CAS-ID | 251565-85-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL282686 |
| ChEBI ID | — |
| PubChem CID | 208901 |
| DrugBank | — |
| UNII ID | 6734037O3L (ChemIDplus, GSRS) |
